New stock news | Lin Qingxuan submitted an application to the Hong Kong Stock Exchange's main board, ranking first among high-end Chinese domestic skincare brands.
According to the disclosure by the Hong Kong Stock Exchange on December 2, Shanghai Lin Qingxuan Cosmetics Group Co., Ltd. has submitted an application to list on the main board of the Hong Kong Stock Exchange, with CITIC Securities and Huatai International as its joint sponsors.
According to the disclosure by the Hong Kong Stock Exchange on December 2, Shanghai Linqingxuan Cosmetics Group Limited (referred to as Linqingxuan) has submitted an application to the main board of the Hong Kong Stock Exchange, with CITIC SEC and Huatai International as its joint sponsors.
The prospectus shows that Linqingxuan is a high-end Chinese skincare brand, focusing on the anti-wrinkle and firming skincare market, and is known for its long-term commitment to providing high-end skincare solutions based on natural camellia oil ingredients under its flagship brand Linqingxuan. Since starting research on camellia skincare products in 2012, the company has pioneered the "nourishing the skin with oil" concept, creating the camellia facial essence oil.
The company's first camellia essence oil was launched in 2014, laying the foundation for the company's core oil-based skincare product line. As of June 30, 2025, the camellia essence oil has sold over 45 million bottles since its launch, and according to data from Zhoushi Consulting, it has consistently ranked first in total retail sales across all facial essence oils for 11 years since 2014. This product is also the only facial essence oil product in China to have retail sales exceeding 1 billion yuan for 8 consecutive years.
Linqingxuan offers a full range of high-end skincare solutions under its brands, including essences, creams, lotions and emulsions, serums, masks, and sunscreens, aiming to support a complete skincare process from cleansing and toning to moisturizing and targeted skincare.
As of June 30, 2025, Linqingxuan offers 230 SKUs. During the reporting periods, Linqingxuan accounted for the vast majority of revenue, with revenue of 685 million yuan, 797 million yuan, 1.198 billion yuan, 525 million yuan, and 1.042 billion yuan for the years 2022, 2023, 2024, and up to June 30, 2025, respectively, accounting for 99.1%, 99.0%, 99.0%, 99.0%, and 99.1% of total revenue for the respective periods.
According to data from Zhoushi Consulting, Linqingxuan ranked first in China among all high-end Chinese skincare brands by retail sales in 2024, holding a 1.4% market share. It is the only Chinese brand among the top 15 high-end skincare brands in China (including domestic and international brands), ranking 13th overall.
The opportunities in the Chinese high-end skincare market are vast. According to data from Zhoushi Consulting, the Chinese high-end skincare market has grown rapidly, from 749 billion yuan in 2019 to 1.144 trillion yuan in 2024, and is expected to reach 2.185 trillion yuan by 2029. In this context, anti-wrinkle and firming are among the key areas of consumer demand. Benefiting from increased consumer demand and the desire to purchase high-quality anti-wrinkle and firming skincare products, this high-end market is expected to experience rapid growth.
The market size for high-end anti-wrinkle and firming products is expected to increase from 594 billion yuan in 2024 to 1.555 trillion yuan in 2029, with a compound annual growth rate of 21.2%. With the widespread acceptance of the "nourishing the skin with oil" and "anti-aging with oil" concepts by consumers, facial essence oils are expected to become classic anti-wrinkle and firming skincare products in the minds of the public. The market size for facial essence oils in China is expected to reach 13.9 billion yuan by 2029, with a compound annual growth rate of 21.3% from 2024 to 2029.
In terms of sales, the company has established a comprehensive sales network, utilizing an OMO (online merging offline) approach, strategically combining diverse online channels with a strong offline presence.
Offline channels include directly operated stores, partner stores, and offline retailers, corporate clients, and dealers. At the same time, the company's online channels include online direct sales and sales to online retailers, providing customers with convenience and access points. This dual approach strengthens brand engagement and drives sustainable growth in all consumer touchpoints.
Financials:
Revenue:
In 2022, 2023, 2024, and up to June 30, 2025, Linqingxuan achieved revenues of approximately 691 million yuan, 805 million yuan, 1.21 billion yuan, and 1.052 billion yuan, respectively.
Gross Profit:
In 2022, 2023, 2024, and up to June 30, 2025, Linqingxuan's gross profit was approximately 539 million yuan, 654 million yuan, 998 million yuan, and 866 million yuan, respectively.
Related Articles

Jiangsu Hengrui Pharmaceuticals (01276) has adjusted 20 products/indications to the new national medical insurance list. Among them, 10 products are included for the first time.

CHINA BOTON (03318) will be suspended from trading starting December 8th for a short period, awaiting the announcement of a significant sale transaction.

GMTEight List of A-share restricted sales and lifting restrictions | December 8th
Jiangsu Hengrui Pharmaceuticals (01276) has adjusted 20 products/indications to the new national medical insurance list. Among them, 10 products are included for the first time.

CHINA BOTON (03318) will be suspended from trading starting December 8th for a short period, awaiting the announcement of a significant sale transaction.

GMTEight List of A-share restricted sales and lifting restrictions | December 8th






